FDA
-
-
-
-
-
-
-
ContraVir Pharma (CTRV) Prices Public Offering with Expected Total Gross Proceeds of Approx. $15.6M
-
-
-
-
-
-
-
ContraVir Pharma (CTRV) Announces 1-for-70 Reverse Stock Split
-
-
-
-
-
-
-
ContraVir Pharma (CTRV) to Present CRV431 Phase 1 Data at EASL
-
-
-
-
-
-
-
ContraVir Pharmaceuticals to Present Two Posters at The Liver Meeting® 2018, Hosted by the American Association for the Study of Liver Diseases
-
-
-
-
-
-
-
ContraVir Pharmaceuticals Completes Data Analysis of Second Cohort in Part 1 of the Phase 1/2a Study of CRV431
-
-
-
-
-
-
-
ContraVir Pharmaceuticals Announces Data on Optimized Formulation of TXL™
-
-
-
-
-
-
-
ContraVir Pharma (CTRV) Says its Inhibitor, CRV431, Reduces Development and Progression of Liver Tumors in Preclinical Hepatocellular Carcinoma Study
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

